146 related articles for article (PubMed ID: 37542081)
1. The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.
Jiang N; Zheng Y; Ding J; Wang J; Zhu F; Wang M; Sobhani N; Neeli P; Wang G; Li H; Zheng J; Chai D
NPJ Vaccines; 2023 Aug; 8(1):109. PubMed ID: 37542081
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus vaccine therapy with CD137L promotes CD8
Ding J; Jiang N; Zheng Y; Wang J; Fang L; Li H; Yang J; Hu A; Xiao P; Zhang Q; Chai D; Zheng J; Wang G
Pharmacol Res; 2022 Jan; 175():106034. PubMed ID: 34915126
[TBL] [Abstract][Full Text] [Related]
3. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8
Zheng Y; Lu Z; Ding J; Jiang N; Wang J; Yang J; Song J; Chen H; Fang L; Li H; Tian H; Wang G; Zheng J; Chai D
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139670
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity.
Chai D; Qiu D; Shi X; Ding J; Jiang N; Zhang Z; Wang J; Yang J; Xiao P; Wang G; Zheng J
Mol Ther Oncolytics; 2022 Mar; 24():1-13. PubMed ID: 34977338
[TBL] [Abstract][Full Text] [Related]
6. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
8. Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8
Chai D; Shan H; Wang G; Zhang Q; Li H; Fang L; Song J; Liu N; Zhang Q; Yao H; Zheng J
Mol Cancer Ther; 2019 Feb; 18(2):323-334. PubMed ID: 30401695
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors.
Ding J; Zheng Y; Zhu F; Wang M; Fang L; Li H; Tian H; Liu Y; Wang G; Zheng J; Chai D
Int Immunopharmacol; 2023 Oct; 123():110722. PubMed ID: 37573687
[TBL] [Abstract][Full Text] [Related]
10. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
11. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.
Chai D; Qiu D; Zhang Z; Yuchen Shi S; Wang G; Fang L; Li H; Li H; Tian H; Zheng J
J Cell Mol Med; 2020 Sep; 24(18):10744-10755. PubMed ID: 32725966
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
Wang X; Li X; Ito A; Sogo Y; Ohno T
Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
[TBL] [Abstract][Full Text] [Related]
14. A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses.
Han X; Gao Z; Cheng Y; Wu S; Chen J; Zhang W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895145
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
16. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
17. Development of a nonhuman primate challenge model to evaluate CD8
Graveline R; Haida M; Dumont C; Poulin D; Poitout-Belissent F; Samadfam R; Kronenberg S; Regenass-Lechner F; Prell R; Piche MS
MAbs; 2022; 14(1):1979447. PubMed ID: 34923919
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
